MedTrace Logo

Intraprostatic PRX302 Injection to Treat Localised Prostate Cancer

NCT03081481 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2019-04-10

No results posted yet for this study

Summary

The purpose of this study is to determine a safe, effective, and tolerable dose of PRX302 for the treatment of low to intermediate risk prostate cancer.

Conditions

Interventions

DRUG

PRX302

Single prostate cancer lesion injected with PRX302

Sponsors & Collaborators

  • Sophiris Bio Corp

    lead INDUSTRY

Principal Investigators

  • Hashim U Ahmed, MD · Imperial College London

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-07
Primary Completion
2018-11-28
Completion
2019-04-05
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03081481 on ClinicalTrials.gov